Discussion about this post

User's avatar
John's avatar

Ground Zero 2025? Putting the CV19 Genie back in the bottle at this stage appears unlikely:

“Last year the Victorian government made a significant $50 million investment to establish mRNA Victoria, an initiative responsible for leading the state’s world-class RNA and mRNA industry. By funding the launch of this Hub, we are in a stronger position than ever to boost local RNA capability and provide vaccine and medicine security for future generations,” Professor Carroll said. The Victorian mRNA Innovation Hub is made up of four primary nodes:

Node 1: Led by Associate Professor Traude Beilharz, Monash Biomedicine Discovery Institute (BDI). The BDI Node houses arguably the highest concentration of RNA researchers in Australia. The scientists have significant experience in mRNA stability; in vitro synthesis and purification of RNA; transcription regulation, and complex RNA design. Their research will lead to the generation of new molecular RNA tools and novel approaches to generate improved mRNA therapeutics.

Node 2: Led by Professor Damian Purcell, Doherty Institute.

Node leader, Professor Purcell, has >30 years’ experience with RNA-research spanning mRNA modification, structure, translation regulation, stability, and viral packaging. The Node will bring together expertise in high containment, in vitro cultivation (SARS-CoV-2, influenza, other), animal infection models, analysis of viral RNA elements, testing of antiviral efficacy and assessment of innate and adaptive antibody and cellular immune responses.

Node 3: Led by Professor Colin Pouton, Monash Institute of Pharmaceutical Sciences (MIPS)

MIPS is the leading national centre for pharmaceutical sciences and Professor Pouton has >30 years’ experience in drug and nucleic acid delivery and has the most well developed mRNA vaccine program in Australia. The MIPS Node brings together broad experience in parenteral

and mucosal drug delivery, targeting to immune cells within the lymph and immune system, pharmacokinetics and drug disposition and expertise in vaccine and drug development. In collaboration with the other nodes MIPS scientists will develop new delivery technologies to promote the utility of next generation mRNA therapeutics.

Node 4: Led by Professor Frank Caruso, Engineering and Information Technology, University

of Melbourne.

The Caruso group is internationally renowned for nanoscience and nanofabrication and is exceptionally well resourced to evaluate the critical interactions that occur at the nanobio interface between nanoparticles and target cells. The Node will combine expertise in delivery engineering with experience in nanomaterial assembly, nanoengineering and gene delivery, along with the development of prototype technologies to investigate novel mRNA delivery systems.

https://www.buildaustralia.com.au/projects/multiplex-to-build-first-australian-mrna-vaccine-manufacturing-facility/

Expand full comment
Julie Pettiford's avatar

Remember Greg Hunt ( health minister) was. WEF graduate, and met with Schwab at the beginning of, and gave his assurances that Australia would comply

Expand full comment
15 more comments...

No posts